TheracosBio focuses on developing novel therapeutics and recently announced the commercial launch of Brenzavvy (bexagliflozin), an FDA‑approved SGLT2 inhibitor. The company’s stated mission is to expand access to new medications for patients with common diseases. Last month’s Brenzavvy launch targets adult patients in the U.S. and the company says it intends to scale distribution and keep pricing affordable. Separately, TheracosBio’s consolidated group has signed a royalty financing agreement tied to a veterinary product that will be commercialized by Elanco Animal Health. Under that agreement TheracosBio received an upfront cash payment in exchange for a portion of future royalties and milestone payments. Management describes the financing as a timely asset to support scaling distribution and broader access. Theracos is a privately-held company based in Marlborough, MA, developing bexagliflozin, an experimental SGLT2 inhibitor for Type 2 diabetes. The company said it raised $25 million in new equity and debt funding to fund development of bexagliflozin. Theracos is recruiting patients for a Phase IIb dosing trial to study the drug's effect on hemoglobin A1c levels. A Phase II trial completed in 2014 showed a statistically significant lowering of HbA1c over a 96-week course of treatment. The financing is intended to support ongoing clinical development and trial activities. The article notes FDA warnings about the SGLT2 inhibitor class and potential risk of diabetic ketoacidosis, which is a relevant regulatory context for the program.

Total raised

$25M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2016